

Philipp Schommers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8796654/publications.pdf>

Version: 2024-02-01

41
papers

2,879
citations

279701

23
h-index

330025

37
g-index

56
all docs

56
docs citations

56
times ranked

5719
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 6, 100122.	3.0	452
2	Swarm Learning for decentralized and confidential clinical machine learning. <i>Nature</i> , 2021, 594, 265-270.	13.7	375
3	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	15.2	342
4	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. <i>Cell</i> , 2020, 182, 843-854.e12.	13.5	310
5	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. <i>Cell Host and Microbe</i> , 2021, 29, 917-929.e4.	5.1	132
6	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	13.5	106
7	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. <i>Nature Medicine</i> , 2019, 25, 1589-1600.	15.2	92
8	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	6.6	85
9	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
10	Poor outcome of HIV-infected patients with plasmablastic lymphoma. <i>Aids</i> , 2013, 27, 842-845.	1.0	57
11	Survival of <sc>AIDS</sc>-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German <sc>HIV</sc> Lymphoma Cohort. <i>British Journal of Haematology</i> , 2015, 168, 806-810.	1.2	53
12	RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2020, 12, 1045.	1.5	53
13	Liver adapts mitochondrial function to insulin resistant and diabetic states in mice. <i>Journal of Hepatology</i> , 2014, 60, 816-823.	1.8	52
14	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
15	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. <i>Cell Host and Microbe</i> , 2022, 30, 69-82.e10.	5.1	42
16	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. <i>Annals of Internal Medicine</i> , 2017, 166, 9.	2.0	41
17	HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. <i>Cell Host and Microbe</i> , 2017, 22, 111-119.e4.	5.1	37
18	openPrimeR for multiplex amplification of highly diverse templates. <i>Journal of Immunological Methods</i> , 2020, 480, 112752.	0.6	36

#	ARTICLE	IF	CITATIONS
19	Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice. <i>Diabetes</i> , 2016, 65, 2540-2552.	0.3	35
20	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.	0.6	34
21	Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. <i>Nature Protocols</i> , 2021, 16, 3639-3671.	5.5	29
22	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	1.7	27
23	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	1.7	27
24	Metformin causes a futile intestinal-â€œhepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state. <i>Molecular Metabolism</i> , 2017, 6, 737-747.	3.0	24
25	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. <i>Microorganisms</i> , 2021, 9, 733.	1.6	22
26	CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. <i>PLoS ONE</i> , 2022, 17, e0268530.	1.1	19
27	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	18
28	Broadly neutralizing antibodies against HIV-1 and concepts for application. <i>Current Opinion in Virology</i> , 2022, 54, 101211.	2.6	18
29	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	1.0	14
30	CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. <i>Aids</i> , 2016, 30, 753-760.	1.0	13
31	Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. <i>British Journal of Haematology</i> , 2021, 194, 642-646.	1.2	12
32	Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. <i>Infection</i> , 2019, 47, 247-255.	2.3	9
33	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. <i>Infection</i> , 2020, 48, 723-733.	2.3	9
34	Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations. <i>Journal of Virology</i> , 2016, 90, 7579-7586.	1.5	8
35	Rapid Response Infrastructures for Pandemic Preparedness in Tertiary Care Hospitals: Lessons Learned from the COVID-19 Outbreak in Germany. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
36	Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 823576.	2.2	1

#	ARTICLE	IF	CITATIONS
37	580. Key Factors for Treatment Changes Within 1 Year After Starting ART in the German ClinSurv Cohort: Between 2005 and 2014. <i>Open Forum Infectious Diseases</i> , 2018, 5, S214-S214.	0.4	0
38	Survival of patients with different AIDS-related lymphoma subtypes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8548-8548.	0.8	0
39	Lymphoma-associated mortality in the German HIV-lymphoma cohort study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7550-7550.	0.8	0
40	Characteristics and Outcome of HIV-Associated Primary Effusion Lymphoma (PEL) As Observed in the German HIV-Related Lymphoma Cohort Study. <i>Blood</i> , 2018, 132, 1719-1719.	0.6	0
41	Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	0.6	0